Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world setting

2020 ◽  
Vol 36 (12) ◽  
pp. 1947-1953
Author(s):  
Yan He ◽  
Xue-Min Gao ◽  
Lei Li ◽  
Xiao-Guang Liu ◽  
Wei Liu ◽  
...  
Keyword(s):  
Real World ◽  
Large Scale ◽  
Surveillance Study ◽  
Real World Setting ◽  
Post Marketing Surveillance ◽  
Post Marketing

scholarly journals Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance

2021 ◽  
Author(s):  
Makoto Tahara ◽  
Naomi Kiyota ◽  
Ken-ichi Nibu ◽  
Ayumi Akamatsu ◽  
Tomohiro Hoshino ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Interstitial Lung Disease ◽  
Head And Neck ◽  
Neck Cancer ◽  
Real World ◽  
Special Interest ◽  
Real World Setting ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Safety Signals

Abstract Background On the basis of phase III CheckMate 141 results, nivolumab was approved for recurrent or metastatic head and neck cancer after undergoing platinum-containing chemotherapy in Japan. This post-marketing surveillance aimed to evaluate the safety and effectiveness of nivolumab for head and neck cancer in the real-world setting. Methods All patients with head and neck cancer who planned to receive nivolumab were centrally registered. This study monitored 607 patients for 6 months to assess nivolumab’s safety, especially treatment-related adverse events (TRAEs) of special interest, and effectiveness. Results TRAEs occurred in 36.1% patients, with no new safety signals. The most common TRAEs with grade ≥ 3 were interstitial lung disease (1.2%), diarrhea (0.8%), and hepatic function abnormal (0.7%). Meanwhile, thyroid dysfunction (10.2%), hepatic dysfunction (5.3%), and interstitial lung disease (4.1%) were the most common TRAE categories of special interest. Although the median time to the onset of each TRAE category of special interest was mostly 1–2 months, most of them occurred throughout the observation period; nonetheless, the majority of patients recovered or remitted. The 6-month survival rate was 55.9%. Conclusion Japanese patients with head and neck cancer treated with nivolumab in the real-world setting manifested no new safety signals. Clinical Trial Registration clinicaltrials.jp: JapicCTI-184071.

Sign in / Sign up

Export Citation Format

Share Document